+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells



Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells



Asian Pacific Journal of Cancer Prevention 14(10): 5663-5669



The histone methyltransferase EZH2 (enhancer of zeste homolog 2) plays critical roles in prostate cancer (PCa) development and is a potential target for PCa treatment. Triptolide possesses anti-tumor activity, but it is unknown whether its therapeutic effect relates with EZH2 in PCa. Here we described EZH2 as a target for Triptolide in PCa cells. Our data showed that Triptolide suppressed PCa cell growth and reduced the expression of EZH2. Overexpression of EZH2 attenuated the Triptolide induced cell growth inhibition. Moreover, Triptolide treatment of PC-3 cells resulted in elevated mRNA levels of target genes (ADRB2, CDH1, CDKN2A and DAB2IP) negatively regulated by EZH2 as well as reduced mRNA levelsan of EZH2 positively regulated gene (cyclin D1). Our findings suggest the PCa cell growth inhibition mediated by Triptolide might be associated with downregulation of EZH2 expression and the subsequent modulation of target genes.

(PDF emailed within 1 workday: $29.90)

Accession: 056694702

Download citation: RISBibTeXText

PMID: 24289559


Related references

The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells. Oncotarget 8(40): 68557-68570, 2017

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. Omics 21(12): 751-753, 2017

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. Omics 20(2): 123-125, 2016

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78(2): 138-143, 2013

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacology and Therapeutics 165: 26-31, 2017

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Molecular Cancer Therapeutics 17(3): 591-602, 2018

Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage. Oncotarget 9(12): 10585-10605, 2018

MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine‚ÄÉ27, and affects thermotolerance acquisition. European Journal of Neuroscience 33(2): 224-235, 2011

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and Therapy 10: 3131-3144, 2017

Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Science 102(7): 1298-1305, 2011

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncology Reports 31(2): 983-988, 2014

Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression. Neoplasma 60(6): 598-604, 2013

Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. Plos One 7(5): E37693, 2012

Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells. Plos One 13(6): E0198351, 2018

Inhibition of histone methyltransferase EZH2 in Schistosoma mansoni in vitro by GSK343 reduces egg laying and decreases the expression of genes implicated in DNA replication and noncoding RNA metabolism. Plos Neglected Tropical Diseases 12(10): E0006873, 2018